Appili Ther - APLIF STOCK NEWS

Aditxt (NASDAQ: ADTX) has signed a second amendment to the arrangement agreement with Appili Therapeutics, targeting a September 30, 2024 closing date for the acquisition. The deal involves Aditxt acquiring all issued and outstanding Class A common shares of Appili through a court-approved plan. Key conditions include Aditxt raising at least US$20 million in financing before closing.

Appili has raised over CAD $100 million since 2015 for developing therapeutics in the global infectious disease and biodefense markets. Their portfolio includes LIKMEZ™, an FDA-approved antibiotic suspension, ATI-1701, a tularemia vaccine, and ATI-1801, a topical antiparasitic product. Two programs are potentially eligible for FDA Priority Review Vouchers, subject to legislation renewal.

Appili Therapeutics reported its fiscal year 2024 results, highlighting the FDA approval and commercial launch of LIKMEZ (ATI-1501) for metronidazole oral suspension. The company secured funding from the U.S. Air Force Academy to advance ATI-1701, a biodefense vaccine, and is engaging with regulatory authorities regarding ATI-1801, a topical antiparasitic product.

Financially, Appili experienced a net loss of $3.8 million, an improvement from the $9.2 million loss in the previous year, aided by an increase in government assistance and revenue. The company reported cash reserves of $0.1 million as of March 31, 2024, compared to $2.5 million the prior year, and highlighted a going concern note due to reliance on closing a transaction with Aditxt and other funding.

Appili entered an agreement with Aditxt, where shareholders would receive a combination of cash and stock, contingent on Aditxt raising additional capital. The deal is expected to finalize by Q3 2024.

Aditxt, Inc. (NASDAQ: ADTX) has entered into an agreement to acquire Appili Therapeutics Inc., a biopharmaceutical company focused on infectious diseases. Appili's assets include the FDA-approved LIKMEZ™, ATI-1701 tularemia vaccine defense program, and ATI-1801 topical formulation. The acquisition aims to enhance Aditxt's portfolio and create synergies in precision diagnostics.

Appili Therapeutics Inc. announces a publication in the journal Frontiers in Bacteriology on the prevention of tularemia in Ukraine, highlighting the potential role of ATI-1701 in biodefense. The company collaborates with Ukrainian and U.S. researchers to assess the risk of tularemia outbreaks in Ukraine, emphasizing the urgent need for protection against infectious diseases. ATI-1701, a first-in-class vaccine candidate, aims to address the lack of approved tularemia vaccines in major global markets, positioning itself as a crucial biodefense solution.

Appili Therapeutics Inc. (APLI) announced that the USPTO has granted a patent for ATI-1701, a biodefense vaccine candidate, providing market exclusivity through 2039. The company also received a pre-IND meeting with the FDA and amended the terms of a bridge loan with Bloom Burton.

Appili Therapeutics Inc. (APLI) announces FDA approval for ATI-1501, branded as LIKMEZ, for the treatment of anaerobic bacterial infections. The company also secured an additional funding commitment of US$14 million from the U.S. Air Force Academy for ATI-1701. Prakash Gowd has been appointed to the Board of Directors. The company reported a net loss and comprehensive loss of $1.0 million for the three months ended September 30, 2023.

Appili Therapeutics secures additional $6.6 million funding for ATI-1701 vaccine program. Total program funding now at $14 million. Change in Board of Directors announced.

Appili Therapeutics announces positive results from annual meeting of shareholders and recent progress in drug development programs.

Appili Therapeutics announces funding commitment from U.S. Air Force for biodefense vaccine candidate ATI-1701